Ancestim clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 1993
How each study uses ancestim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Brand
- Stemgen
- 1
Studies by the year they started
4 studies that test it; most in 1993 (1)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1998 | 1 |
| 2000 | 1 |
| 2007 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
National Heart, Lung, and Blood Institute (NHLBI) (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Peter MacCallum Cancer Centre, Australia (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ancestim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of MyelodysplasiaStatus unknownEarly Phase 1Peter MacCallum Cancer Centre, AustraliaNCT00434239Written as Lenalidomide + Ancestim
- Comparing Treatments for Multiple MyelomaCompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT00001750Written as Stemgen
- A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling DisordersCompletedPhase 1National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00005783Written as Recombinant-methionyl human stem cell factor
- Stem Cell Factor Medication for Aplastic AnemiaCompletedPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT00001398Written as Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
Given beside what is tested · 1 — ancestim is usual care or a partner of the new treatment
Codes
What other systems call ancestim · ClinicalTrials.gg INT003979
- MeSH (NLM) C105861ancestimOne source NLM
- UNII (FDA) PYB4Q6JG41ANCESTIMConfirmed FDA, NLM, Wikidata
- RxNorm 140502Confirmed FDA, Wikidata
- Wikidata Q4752549ancestimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1646AncestimOne source FDA
- DrugBank DB09103One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C105861 | ancestim | One source NLM |
| UNII (FDA) | PYB4Q6JG41 | ANCESTIM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 140502 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4752549 | ancestim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1646 | Ancestim | One source FDA |
| DrugBank | DB09103 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.